| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AZU1 |
| Uniprot No | P20160 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-250aa |
| 氨基酸序列 | IVGGRKARPRQFPFLASIQNQGRHFCGGALIHARFVMTAASCFQSQNPGV STVVLGAYDLRRRERQSRQTFSISSMSENGYDPQQNLNDLMLLQLDREAN LTSSVTILPLPLQNATVEAGTRCQVAGWGSQRSGGRLSRFPRFVNVTVTP EDQCRPNNVCTGVLTRRGGICNGDGGTPLVCEGLAHGVASFSLGPCGRGP DFFTRVALFRDWIDGVLNNPGPGP |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AZU1重组蛋白的3篇代表性文献示例(注：内容基于领域常见研究方向模拟，建议通过学术数据库核实具体文献)：
1. **《Recombinant AZU1 exhibits potent antimicrobial activity against Gram-negative pathogens》**
- 作者：Zhang Y, et al.
- 摘要：研究报道了通过大肠杆菌表达系统成功制备重组AZU1蛋白，并证实其对大肠杆菌和铜绿假单胞菌等革兰氏阴性菌具有浓度依赖的杀菌作用，揭示了其与细菌膜结合破坏完整性的机制。
2. **《Structural insights into the heparin-binding domain of AZU1 and its immunomodulatory function》**
- 作者：Pereira HA, et al.
- 摘要：通过X射线晶体学解析了重组AZU1的肝素结合结构域三维结构，发现该区域通过结合宿主细胞表面硫酸乙酰肝素介导单核细胞趋化，提示其在炎症反应中的双重角色(抗菌与促炎)。
3. **《Recombinant AZU1 exacerbates sepsis-induced lung injury via neutrophil extracellular trap formation》**
- 作者：Lee WL, et al.
- 摘要：在小鼠脓毒症模型中，外源性重组AZU1通过诱导中性粒细胞释放NETs(胞外诱捕网)，加重肺组织损伤，提示其作为潜在治疗靶点的复杂性。
建议使用PubMed或Web of Science以“recombinant AZU1 protein”或“azurocidin expression”为关键词检索近5年文献，获取最新进展。
**Background of AZU1 Recombinant Protein**
AZU1 (Azurocidin 1), also known as heparin-binding protein (HBP) or CAP37. is a multifunctional protein primarily expressed in neutrophils. It is stored in azurophilic granules and released during neutrophil activation, playing critical roles in innate immunity and inflammatory responses. Structurally, AZU1 belongs to the serine protease family but lacks enzymatic activity due to amino acid substitutions in its catalytic triad. Instead, it exhibits potent antimicrobial, chemotactic, and immunomodulatory properties.
The recombinant AZU1 protein is engineered using biotechnological platforms (e.g., *E. coli*, mammalian cells) to produce a purified, biologically active form. This allows researchers to study its mechanisms without relying on native neutrophil sources. Recombinant AZU1 retains key functions, including binding to glycosaminoglycans and lipopolysaccharides (LPS), which underlies its ability to neutralize pathogens and modulate endothelial permeability.
AZU1’s role in inflammation is dual-natured: it promotes leukocyte recruitment to infection sites but can also exacerbate tissue damage in sepsis or chronic inflammatory diseases. Its involvement in conditions like sepsis, rheumatoid arthritis, and atherosclerosis has spurred interest in therapeutic targeting. Recombinant AZU1 serves as a tool to explore these pathways, aiding drug development and biomarker research.
Additionally, studies highlight its potential in wound healing and angiogenesis, attributed to its growth factor-like properties. However, its precise signaling mechanisms remain under investigation. Overall, recombinant AZU1 is a vital reagent for dissecting neutrophil-mediated immunity and developing interventions for infections and inflammatory disorders.
×
